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現在,我々は, 5-fluorouracil (5-FU)とcisplatin (CDDP)を主体とし
た術前癌化学療法を行っているが,本研究では,近年, 5-FUの分解にお
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を落め,急性腎不全,低Na. Cl血症(Na: 123mEq4, Cl: 88血Rq4),低タンパ
ク･低アルブミン血症(総タンパク:3.2g/dl,アルブミン: 1.5g/dlまで低下),
低栄養(コリンエステラーゼ: 538IU4),骨髄抑制,貧血(RBC:250万/FEl,


























いものの, WBC, CRPが上昇し始め, 6月14日の検査で, WBC: 10330/FEl,
CRP: 4.14mg/dlで,胸部Ⅹ線写真で両側肺野に陰影を蔑めたため,静燕性肺炎
等を疑い,同日より抗生物質の投与を開始.ところが, 6月17日の検査で,


































悪心･･唱吐; 8日目より出現(Grade2)  (Grade4)
脱水; Grade3
Grade ･･ NationalCancer Institute Common Toxicity Criteria























































































とく, Ba又, Caspase-2, 3,.8, 9とも枠で囲んだドナーのPBMCにおいて,コン
トロールに比べて各mRNAの発現の増強が認められた.
一方,アポトーシス抑制タンパクも,図5のように枠で囲んだドナーのPBMC





促進タンパクであるFas, Ba又, Caspase-2, 3, 8, 9のmRNAの発現が増強し













































(10FLg/mt) (1 0Ftg/ml) (各1 0JLg/ml)
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9. -次抗体: EM1915　6.83mg血1 ×100,
EM1919　　3mg/d XIOO, 4℃　over血ght
10. PBSで洗浄, 4℃, 3回.
ll.二次抗体:ビオチン標識抗マウスIgG(Vector Laboratories, Inc･),室温,
30分.
12. PBSで洗浄, 4℃, 3回.
13. ABC Kt (Vector Laboratories, Inc.),室温, 30分.
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ナノバブルを用いた薬剤導入と抗鹿癌効果の検討
Drug iJLduction and atLti-Cancer eJrects tISiJlg tLanObubbleswith ultrasound
はじめに










293T (ヒト胎児腎細胞株)､ーbtF7 (ヒト乳癌細胞株)､ C.lon26 (マウス結腸癌細胞
秩)､ EMT6 (マウス乳癌細胞株)を細胞数5Ⅹ104cells / yellで48 well平底プレー




















1 Tsutsui JM, Ⅹie F, Porter RT. The use ofmicrobubbles to target drug delivery.
Cwdt'ovasc tHtrasound 2004; 2: 23.
2　　KodaJna T, H血blin MR, Doukas AG. Cytoplasmic molecular deliverywithShock
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ナノバブルによる5-FUおよびCDDPの抗鹿癌効果の増強
Abstmct
We report on the use of gas-encapsulated nanobubbles OJB) delivered by ultrasound ⅣS) to
permeabilize cancer cellsand potentialte the cytotoxicity of anti-caner drug (cisplatinand 5-FU).
We studied 293T (hmankidney cells), MCF7 (human breast adenocarci.noma), EMT6 (murine
maJnmary CarCinoma) and colon 26 cells (murine recttm carcinoma) uslng CytOtOXicity assays
(m assay)･ Plasmid DNA (expressing EGFP or lucifTerase) was used for optimizingultrasonlC
conditions･ NB (10% V/V)withUS (pressure 0.96MPa) produced sigmi鮎ant cytotoxicitynot
seenwitheither ultrasound or drugalone･ Increasingthe duty ratio of US up to 80% Mer
increased cytotoxicity･ We proposed a hypothesis that sub-nanobubbles (cavitation bubbles) are
produced by collapsed of hanobubblesand shock waves generated舟om by the cavitation
bubbles lead to the transient membranepermeability, followed by entry of plasmid DNA and
drug･ Fromthe observation of rapid collapse of nanobubbleswithultrasound, we hypnotized
that cavitadon bubbles produced &omthe nanobubbles generated shock waves, resulting inthe
membranepermeability,followed by entry of anticancer drugs.
緒　言















293T (ヒト胎児腎細胞株)､ MCF7 (ヒト乳癌細胞株)､ colon26 (マウス結腸癌細胞
#;The Cell Resource Center for Bionedical Research, Institute of Development,




レポーター連伝子､ pGL3-Control luciferase reporter vector (5256bp, Promega,
WI, USA), PEGFP-NI vector (4.7kb, BD Clontech, CA, USA )を用いて分子導入効率
をおこない､超音波照射条件を最適化した｡
2-1-3超音波　　　　　　　　　　　　　　　　　　　　,
超音波プローブ(周波数945kHz, Fuji Ceramics Co., Fujinomiya, Japan)は増幅
器(HSA4101, DC～10NHz, NF Co.,Yokohama, Japan)を介して､パルス発生器(WF
1945A,周波数帯域は0.01 ･Hz-15MHz , NF Co.,Yokohama, Japan)で駆動した.
超音波の音圧は増幅器(AIOl, Specialty Engineering Associates, Sam Diego, CA, USA)
を介してPVDFニードルハイドロフォン(PZTZ44-loo°, Specialty Engineering
Associates,　周　波　数　帯　域　は0.25-20NHz)で検知した｡ハイドロフォン　で
出力された信号はデジタルオシロスコープ(wave surfer454,600MIIz, lM gl (16　pF),
LeCioy co., chestnut Ridge, NY,USA)で計測する｡超音波照射条件はデューティ比
が10-80%,圧力が0,96MPaであった｡
2-1-4ナノバブル
アルブミンバブル(Optison T甘,Amersham Helth, Oslo, Norway)と脂質バブル
( PEGIPC )を用いた｡脂質バブルの作製は2mg/nL distearoyl phosphatidylcholine
(PC) ( Avanti Polar Lipids, Alabaster, AL ) ､ 1mg/mL polyethleneglyco1-40
stearate (PEG) ( Sigma Chemical Co., St. Louis, MO)をPBS (1Ⅹ)に溶解し､注
射針にて液層にC,F8を投与しながらソニケ-ションをおこない作製した.バブル作製




シスプラチン(Randa●, Nippon Kayaku Co., Tokyo, Japan )と5TFU (Kyowa Hakko
Kogyo Co･ , Tokyo, Japan)を各濃度条件下(0. 1-1000pM)で作用させた｡
2-2方法
2-2-1細胞培養と遺伝子導入
各種細胞株は細胞数5Ⅹ104 cells / vellで48 well平底プレートに播種し､ 293T細
胞､ EMT6細胞は10%FBS ､ 1%ペニシリン-ストレプトマイシン含有DMEM培地(Sigma
Chemical Co･, St. Louis, MO )､ MCF7細胞､ Colon26細胞はRPM1640培地(Sigma










































Lipid-bubble size was measured with SALD_2200.
Size : 440土20 mm









Duty ratio (%) 0 2050805080 0 2090eD5080 0 205000508EI 0 208060508D
CoHs　　　293T Colon26　EMT6　MCF7
Fig･2 LtlCiferase activity
The optimized ultrasomic conditions were determinedwith the intensityof gene expression
activity･ Cells were plated in 48-well tissue culture plates in complete mediumand incubated for
24 h･ Cells weremixedwith 4pg / mL plasmid DNA ( luciferase or EGFP)with lO%V/v of
albumin-NB (ANB) or lipid-NB (LNB), and exposed to US (1MHz, 80% dutycycle, 0.96MPa).
After 24 h, LucifTerase activity and EGFP expression were measured.
Fig･3 EGFP ExpressioJ)
Percentage ofEGFP Expression ; A‥293T(35%), B:Colon26(4.5%),C:EMT6( I 5%),
D : MCF7(2 6%).
Thepercentage was obtainedwith加w cytometry･
Contro1 293T Colon26 EMT6　MCF7
Fig･4 Mediatl Fluorescence Intensity (MFI) of EGFP































Fig･5 EnbJICemeAt Of drug st]sceptibility
The effect of US and Nanobubbles (albmin-NB or lipid-NB ) onthe sensitivityto (A) 5･FU
and P) CDDP･ Four different cell lines were exposed to USunder the optimized conditionwith
various concentrations of 5-FU or CDDP and cultured for 24 h･ The cellviability was estimated
by MTT assay･ NB enhanced the drug susceptibility effectively'resulting in cytotoxicity･
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